logo

Xeris Pharmaceuticals Inc (XERS)



Trade XERS now with
  Date
  Headline
5/11/2022 7:24:15 AM Xeris Biopharma Q1 Net Loss $33.7 Mln Or $0.25/Shr Vs Loss Of $18.4 Mln Or $0.30/shr Last Year
3/10/2022 7:12:31 AM Xeris Biopharma Q4 Net Loss $50.8 Mln Or $0.42/shr Vs Net Loss Of $21.9 Mln Or $0.41/shr Prior Year
1/31/2022 7:12:20 AM Xeris Says Recorlev Commercially Available For Treatment Of Endogenous Hypercortisolemia With Cushing's Syndrome
1/18/2022 7:06:36 AM Xeris Biopharma Reaffirms 2021 Pro Forma Net Sales Guidance
1/3/2022 7:04:47 AM Xeris Biopharma Agrees For $30 Mln Private Placement
12/16/2021 7:17:19 AM Tetris Pharma Launches Ogluo In United Kingdom And It Is Now Available By Prescription For Severe Hypoglycemia
10/25/2021 7:38:23 AM Xeris Pharma Collaborates With Merck On XeriJect; Stock Surges
9/14/2021 4:09:28 PM Xeris Pharmaceuticals Stockholders Approve Acquisition Of Strongbridge Biopharma
9/1/2021 7:33:39 AM Xeris Pharma Completes Enrollment Of Phase 1 Study Of Levothyroxine
8/23/2021 8:06:20 AM Xeris Pharmaceuticals Announces Gvoke Kit SNDA Approval For The Treatment Of Severe Hypoglycemia
8/5/2021 7:17:35 AM Xeris Pharmaceuticals Q2 Loss/shr $0.41 Vs. Loss/shr $0.63 Last Year
7/19/2021 8:04:44 AM Xeris Enters Into License And Supply Agreement With Tetris Pharma To Commercialize Ogluo In Europe
7/2/2021 4:11:51 PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)